Entero Therapeutics, Inc.
ENTO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $8,263 | $5,718 | $6,862 | $8,890 |
| - Cash | $2,517 | $4 | $59 | $163 |
| + Debt | $836 | $836 | $836 | $141 |
| Enterprise Value | $6,582 | $6,549 | $7,638 | $8,867 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$935 | -$639 | -$930 | -$1,204 |
| % Margin | – | – | – | – |
| Net Income | -$1,153 | -$998 | -$1,260 | -$12,238 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.75 | -0.21 | -0.28 | -2.57 |
| % Growth | -257.1% | 25% | 89.1% | – |
| Operating Cash Flow | -$856 | -$55 | -$819 | -$172 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$856 | -$55 | -$819 | -$172 |